Orchard Therapeutics, a commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, has announced two additions to its global commercial leadership team, appointing Robin Kenselaar as senior vice president and general manager, EMEA commercial operations and Brad Mathis as vice president, US commercial operations.
These two key appointments serve to build Orchard's initial commercial infrastructure across North America and EMEA prior to the company's first three potential product launches. Robin and Brad will report to Jason Meyenburg, chief commercial officer.
"We are thrilled to welcome Robin and Brad to the Orchard team, with their decades of experience and proven success leading international and domestic commercial operations for companies targeting rare diseases,” said Jason Meyenburg. “With three submissions for product approvals anticipated over the next three years and several additional therapies in development, the recent expansion of our commercial leadership team marks an important milestone as we prepare for the potential launches of these late-stage gene therapies, focusing especially on market access preparations and further development of patient diagnosis pathways."
Robin Kenselaar joins Orchard after almost 15 years at Sanofi Genzyme, where he built and led commercial operations throughout Europe for therapies addressing unmet needs such as rare genetic diseases, oncology and immunology.
Brad Mathis brings extensive global and domestic experience in product commercialisation and launches, as well as pharmaceutical sales and marketing, with a focus on rare diseases.
